NASDAQ:LGVN
Longeveron Inc. Stock News
$1.75
+0.0800 (+4.79%)
At Close: Apr 26, 2024
Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer's Trial
12:03pm, Wednesday, 13'th Apr 2022 InvestorsHub
Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer's Trial This third collaboration with the Miami VA shows Longeveron's commitment to improving the health of our nation's Veterans. Miami, Florida - April 13, 2022 -- InvestorsHub NewsWire -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-th...
5 Short Squeeze Candidates To Watch: Aterian Tops The List, System1 Group And Longeveron Join Leaderboard
10:34am, Monday, 11'th Apr 2022
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
05:02pm, Friday, 08'th Apr 2022
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech S
Longeveron publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer's Disease in Alzheimer's & Dementia©: The Journal of the Alzheimer's Association
12:28pm, Thursday, 31'st Mar 2022 InvestorsHub
Longeveron publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer's Disease in Alzheimer's & Dementia©: The Journal of the Alzheimer's Association
Results Support Further Exploration of Therapeutic Potential of Lomecel-B to Slow Cognitive Decline, Improve Quality of Life for Alzheimer's Patients.
Phase 2 Trial Recently Launched with First Patient Treated.
Miami– March 31, 2022 - InvestorsHub NewsWire --&nb...
Alzheimer's News: Why Is Drugmaker Longeveron (LGVN) Soaring Today?
12:06pm, Thursday, 31'st Mar 2022
Longeveron (LGVN) stock is taking off on Thursday after the drugmaker published news related to an Alzheimer's treatment. The post Alzheimer's News: Why Is Drugmaker Longeveron (LGVN) Soaring Today?
Why Longeveron Shares Are Surging Today
10:06am, Thursday, 31'st Mar 2022
Longeveron Inc (NASDAQ: LGVN) shares are trading higher Thursday after the company announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer's diseas
5 Cheap Energy Stocks Riding Oil Higher
01:56pm, Wednesday, 23'rd Mar 2022
Energy is understandably at the top of every investor's mind right now, but finding the best energy stocks requires careful consideration. The post 5 Cheap Energy Stocks Riding Oil Higher appeared fir
My No. 2 Stock Pick For 2022 Rises 100%…
04:54pm, Tuesday, 15'th Mar 2022
There isn't just one kind of good stock, and there isn't just one good strategy for when to sell. You need a variety of approaches.
Longeveron to Present at Oppenheimer 32nd Annual Healthcare Conference
08:00am, Tuesday, 15'th Mar 2022
MIAMI, March 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related a
Longeveron Inc. (LGVN) CEO Geoff Green on Q4 2021 Results - Earnings Call Transcript
09:50pm, Friday, 11'th Mar 2022 Seeking AlphaLongeveron Inc. (LGVN) CEO Geoff Green on Q4 2021 Results - Earnings Call Transcript
04:50pm, Friday, 11'th Mar 2022
Longeveron Inc. (LGVN) CEO Geoff Green on Q4 2021 Results - Earnings Call Transcript
Longeveron slips after Q4 earnings amid likely delay in key data readout
01:36pm, Friday, 11'th Mar 2022 Seeking Alpha
The clinical-stage biotechnology company Longeveron (LGVN) has lost ~10% in the pre-market Friday after the company signaled a potential delay for results from its Aging Frailty trial…
Longeveron GAAP EPS of -$0.20 beats by $0.05, revenue of $0.21M
01:02pm, Friday, 11'th Mar 2022 Seeking Alpha
Longeveron press release (LGVN): Q4 GAAP EPS of -$0.20 beats by $0.05.Revenue of $0.21M (-82.2% Y/Y).CEO comment: “Since our IPO in February of last year, important progress has…
Earnings Scheduled For March 11, 2022
09:09am, Friday, 11'th Mar 2022 Benzinga
Companies Reporting Before The Bell • The Real Good Food (NASDAQ: RGF ) is estimated to report quarterly loss at $0.19 per share on revenue of $25.29 million. • Smart Share Global (NASDAQ: EM ) is expected to report quarterly loss at $0.04 per share on revenue of $129.31 million. • Longeveron (NASDAQ: LGVN ) is projected to report quarterly loss at $0.25 per share on revenue of $260.00 thousand. • Sunworks (NASDAQ: SUNW ) is likely to report quarterly loss at $0.17 per share on revenue of $31.40 million. • Drive Shack (NYSE: DS ) is likely to report quarterly loss at $0.13 per share on revenue of $69.26 million. • Hudson Global (NASDAQ: HSON ) is likely to report quarterly earnings at $0.46 per share on revenue of $46.25 million. • RLX Technology (NYSE: Full story available on Benzinga.com
Foreshadowing Stock: Longeveron Inc. (NASDAQ:LGVN), Denison Mines Corp. (AMEX:DNN)
06:25am, Friday, 11'th Mar 2022 Stock Equity
Longeveron Inc. (NASDAQ:LGVN) with the stream of -1.84% also noticed, India Denison Mines Corp. (AMEX:DNN) encountered a rapid change of 1.73% in the last hour of Thursday’s trading session. Longeveron … The post Foreshadowing Stock: Longeveron Inc. (NASDAQ:LGVN), Denison Mines Corp. (AMEX:DNN) appeared first on Stocks Equity .